Bromide

Bromide

SCHEMBL5830128

FCCC[P+](c1ccccc1)(c1ccccc1)c1ccccc1.[Br-]

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.61
ALDH1A1 P00352 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
TSHR P16473 1/20 0.47
CYP2C19 P33261 1/20 0.47
CHRNA7 P36544 9/20 0.42
TRAP1 Q12931 2/20 0.38
SNCA P37840 2/20 0.37
HTR2A P28223 1/20 0.35
HRH1 P35367 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL2971315 0.93 HIF1A (0.58) HIF1AALDH1A1CYP1A2CYP2D6TSHR
Bromide SCHEMBL2446042 0.85 HIF1A (0.74) HIF1AALDH1A1CYP1A2CYP2D6TSHR
Bromide SCHEMBL2449969 0.85 HIF1A (0.74) HIF1AALDH1A1CYP1A2CYP2D6TSHR
Bromide SCHEMBL3391859 0.83 HIF1A (0.70) HIF1AALDH1A1CYP1A2CYP2D6TSHR
Bromide SCHEMBL2450121 0.83 HIF1A (0.70) HIF1AALDH1A1CYP1A2CYP2D6TSHR
Bromide SCHEMBL7634128 0.83 HIF1A (0.70) HIF1AALDH1A1CYP1A2CYP2D6TSHR
Bromide SCHEMBL4184421 0.83 HIF1A (0.70) HIF1AALDH1A1CYP1A2CYP2D6TSHR
Bromide SCHEMBL52420 0.83 HIF1A (0.70) HIF1AALDH1A1CYP1A2CYP2D6TSHR
Bromide SCHEMBL8761335 0.83 HIF1A (0.70) HIF1AALDH1A1CYP1A2CYP2D6TSHR
SCHEMBL31146915 0.83 HIF1A (0.78) HIF1AALDH1A1CYP1A2CYP2D6TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8524193-B2 Non-invasive diagnostic imaging technology for mitochondria using radiolabeled lipophilic salts THE JOHNS HOPKINS UNIVERSITY (US) 2013-09-03 US disclosed
CN-101838289-A Non-invasive diagnostic imaging technology for mitochondria using radiolabeled lipophilic salts UNIV JOHNS HOPKINS 2010-09-22 CN disclosed
CN-100577213-C Non-invasive diagnostic imaging technique for mitochondrial dysfunction using radioisotope labeled lipophilic salts UNIV JOHNS HOPKINS 2010-01-06 CN disclosed
US-7112318-B2 Phosphonium or quaternary ammonium salts labeled with 11C, 18F,76Br, or 123I; for positron emission tomography; capable of measuring mitochondrial surface potential; localize into dysfunctional mitochondria THE JOHNS HOPKINS UNIVERSITY (US) 2006-09-26 US disclosed
US-20050182027-A1 radiolabeled phosphonium or ammonium salts that accumulate in mitochondria of cancer cells; cancer diagnosis; tomography; distinguishes between tissue inflammation and tumors; e.g. F18-3-fluoropropyltriphenyl phosphonium bromide NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-08-18 US disclosed
CN-1627962-A Non-invasive diagnostic imaging technique for mitochondrial dysfunction using radioisotope labeled lipophilic salts UNIV JOHNS HOPKINS (US) 2005-06-15 CN disclosed
EP-1474177-A2 NON-INVASIVE DIAGNOSTIC IMAGING TECHNOLOGY FOR MITOCHONDRIA USING RADIOLABELED LIPOPHILIC SALTS The John Hopkins University (US) 2004-11-10 EP disclosed
US-20040033197-A1 Phosphonium or quaternary ammonium salts labeled with 11C, 18F,76Br, or 123I; for positron emission tomography; capable of measuring mitochondrial surface potential; localize into dysfunctional mitochondria THE JOHNS HOPKINS UNIVERSITY (US) 2004-02-19 US disclosed
WO-2003065882-A2 NON-INVASIVE DIAGNOSTIC IMAGING TECHNOLOGY FOR MITOCHONDRIA USING RADIOLABELED LIPOPHILIC SALTS THE JOHNS HOPKINS UNIVERSITY (US) 2003-08-14 WO disclosed
EP-0679707-B1 Liquid crystalline compound, liquid crystal composition and liquid crystal display element CHISSO CORP (JP) 1999-06-16 EP disclosed
US-5720899-A Liquid crystalline compound, liquid crystal composition and liquid crystal display element CHISSO CORPORATION (JP) 1998-02-24 US disclosed
US-5653911-A Liquid crystalline compound liquid crystal composition and liquid crystal display element CHISSO CORPORATION (JP) 1997-08-05 US disclosed
EP-0679707-A1 Liquid crystalline compound, liquid crystal composition and liquid crystal display element Chisso Corporation (JP) 1995-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182027-A1 radiolabeled phosphonium or ammonium salts that accumulate in mitochondria of cancer cells; cancer diagnosis; tomography; distinguishes between tissue inflammation and tumors; e.g. F18-3-fluoropropyltriphenyl phosphonium bromide SLC8B1, TFAM, MT-ATP8 HIF1A 600/4885ALDH1A1 4697/4885CYP1A2 4427/4885
US-20040033197-A1 Phosphonium or quaternary ammonium salts labeled with 11C, 18F,76Br, or 123I; for positron emission tomography; capable of measuring mitochondrial surface potential; localize into dysfunctional mitochondria ATP5PB, MCU, ATP5PD HIF1A 691/4885ALDH1A1 3981/4885CYP1A2 3787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.